<DOC>
	<DOCNO>NCT01246752</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation patient newly diagnose AML ≤60 year age intermediate risk , first complete response comparison standard consolidation chemotherapy</brief_summary>
	<brief_title>Haematopoietic Stem Cell Transplantation ( HSCT ) Comparison Conventional Consolidation Therapy Patients With Acute Myeloid Leukemia ( AML ) ( Intermediate Risk ) &lt; = 60y . After First CR</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>AML first remission cytological standard risk , i.e . karyotype list exclusion criterion Identification HLAidentical sibling HLAcompatible related unrelated donor ( 9/10 HLAalleles match , high resolution type HLAA , B , Cw , DRB1 DQB1 ) age : 18 60 year medically fit allogeneic stem cell transplantation CR / CRi induction therapy corebinding factor leukemia ( ( 8 ; 21 ) , inv16 ) acute promyelocytic leukemia ( ( 15 ; 17 ) complex aberrant karyotype karyotype : 7 ; 5 ; del5q ; ( 3 ; 3 ) ; ( 6 ; 11 ) , ( 6 ; 9 ) , 11q aberration , trisomy 8 ± one single additional aberration pregnancy / nursing noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>AML , Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>HSCT</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Tx</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>